Literature DB >> 19218531

Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides.

Michael T Bethune1, Matthew Siegel, Samuel Howles-Banerji, Chaitan Khosla.   

Abstract

Celiac sprue is a T-cell-mediated enteropathy elicited in genetically susceptible individuals by dietary gluten proteins. To initiate and propagate inflammation, proteolytically resistant gluten peptides must be translocated across the small intestinal epithelium and presented to DQ2-restricted T cells, but the effectors enabling this translocation under normal and inflammatory conditions are not well understood. We demonstrate that a fluorescently labeled antigenic 33-mer gluten peptide is translocated intact across a T84 cultured epithelial cell monolayer and that preincubation of the monolayer with media from gluten-stimulated, celiac patient-derived intestinal T cells enhances the apical-to-basolateral flux of this peptide in a dose-dependent, saturable manner. The permeability-enhancing activity of activated T-cell media is inhibited by blocking antibodies against either interferon-gamma or its receptor and is recapitulated using recombinant interferon-gamma. At saturating levels of interferon-gamma, activated T-cell media does not further increase transepithelial peptide flux, indicating the primacy of interferon-gamma as an effector of increased epithelial permeability during inflammation. Reducing the assay temperature to 4 degrees C reverses the effect of interferon-gamma but does not reduce basal peptide flux occurring in the absence of interferon-gamma, suggesting active transcellular transport of intact peptides is increased during inflammation. A panel of disease-relevant gluten peptides exhibited an inverse correlation between size and transepithelial flux but no apparent sequence constraints. Anti-interferon-gamma therapy may mitigate the vicious cycle of gluten-induced interferon-gamma secretion and interferon-gamma-mediated enhancement of gluten peptide flux but is unlikely to prevent translocation of gluten peptides in the absence of inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19218531      PMCID: PMC2672868          DOI: 10.1124/jpet.108.148007

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

1.  Activation of macrophages by gliadin fragments: isolation and characterization of active peptide.

Authors:  Ludmila Tucková; Jana Novotná; Petr Novák; Zuzana Flegelová; Tomás Kveton; Lenka Jelínková; Zdenek Zídek; Petr Man; Helena Tlaskalová-Hogenová
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

2.  Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment.

Authors:  Andrei I Ivanov; Asma Nusrat; Charles A Parkos
Journal:  Mol Biol Cell       Date:  2003-10-03       Impact factor: 4.138

3.  Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms.

Authors:  Matthias Bruewer; Andreas Luegering; Torsten Kucharzik; Charles A Parkos; James L Madara; Ann M Hopkins; Asma Nusrat
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion.

Authors:  Shuo-Wang Qiao; Elin Bergseng; Øyvind Molberg; Jiang Xia; Burkhard Fleckenstein; Chaitan Khosla; Ludvig M Sollid
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

5.  High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue.

Authors:  Justin L Piper; Gary M Gray; Chaitan Khosla
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

6.  The interferon gamma gene in celiac disease: augmented expression correlates with tissue damage but no evidence for genetic susceptibility.

Authors:  Martin C Wapenaar; Martine J van Belzen; Justin H Fransen; Aranzazu Fariña Sarasqueta; Roderick H J Houwen; Jos W R Meijer; Chris J J Mulder; Cisca Wijmenga
Journal:  J Autoimmun       Date:  2004-09       Impact factor: 7.094

Review 7.  A porous defense: the leaky epithelial barrier in intestinal disease.

Authors:  Daniel R Clayburgh; Le Shen; Jerrold R Turner
Journal:  Lab Invest       Date:  2004-03       Impact factor: 5.662

8.  Structural basis for gluten intolerance in celiac sprue.

Authors:  Lu Shan; Øyvind Molberg; Isabelle Parrot; Felix Hausch; Ferda Filiz; Gary M Gray; Ludvig M Sollid; Chaitan Khosla
Journal:  Science       Date:  2002-09-27       Impact factor: 47.728

9.  Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue.

Authors:  M Schumann; J F Richter; I Wedell; V Moos; M Zimmermann-Kordmann; T Schneider; S Daum; M Zeitz; M Fromm; J D Schulzke
Journal:  Gut       Date:  2008-02-27       Impact factor: 23.059

Review 10.  Parallels between pathogens and gluten peptides in celiac sprue.

Authors:  Michael T Bethune; Chaitan Khosla
Journal:  PLoS Pathog       Date:  2008-02       Impact factor: 6.823

View more
  16 in total

1.  New and developing therapies for celiac disease.

Authors:  Christina A Tennyson; Suzanne K Lewis; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

2.  Selected Probiotic Lactobacilli Have the Capacity To Hydrolyze Gluten Peptides during Simulated Gastrointestinal Digestion.

Authors:  Ruggiero Francavilla; Maria De Angelis; Carlo Giuseppe Rizzello; Noemi Cavallo; Fabio Dal Bello; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2017-06-30       Impact factor: 4.792

Review 3.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

4.  Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.

Authors:  T Rauhavirta; S-W Qiao; Z Jiang; E Myrsky; J Loponen; I R Korponay-Szabó; H Salovaara; J A Garcia-Horsman; J Venäläinen; P T Männistö; R Collighan; A Mongeot; M Griffin; M Mäki; K Kaukinen; K Lindfors
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

5.  Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy.

Authors:  Thomas R Diraimondo; Cornelius Klöck; Chaitan Khosla
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

Review 6.  Review article: coeliac disease, new approaches to therapy.

Authors:  S Rashtak; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2012-02-13       Impact factor: 8.171

7.  Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques.

Authors:  Kaushiki Mazumdar; Xavier Alvarez; Juan T Borda; Jason Dufour; Edith Martin; Michael T Bethune; Chaitan Khosla; Karol Sestak
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

8.  Noninflammatory gluten peptide analogs as biomarkers for celiac sprue.

Authors:  Michael T Bethune; Mónica Crespo-Bosque; Elin Bergseng; Kaushiki Mazumdar; Lara Doyle; Karol Sestak; Ludvig M Sollid; Chaitan Khosla
Journal:  Chem Biol       Date:  2009-08-28

Review 9.  Current and emerging therapy for celiac disease.

Authors:  Govind K Makharia
Journal:  Front Med (Lausanne)       Date:  2014-03-24

Review 10.  Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy.

Authors:  Jürgen Stein; Detlef Schuppan
Journal:  Viszeralmedizin       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.